Low-Dose Chemotherapy – Can It Work For Men Who Are Unable To Tolerate Normal Doses?

A study conducted at The Department of Urology, Yokosuka Kyosai Hospital, Japan, evaluated the efficacy and safety of using a low-dose chemotherapy combination of docetaxel, estramustine and dexamethasone in men with castrate resistant prostate cancer (CRPC). The study enrolled sixty-nine with CRPC. Docetaxel dosage was downed to 25 mg/m2 on days 1 and 8 every [...]

Estramustine Plus Docetaxel After A Vacation as Second-Line Therapy in Patients with Hormone-Refractory Prostate Cancer Resistant to Docetaxel

What is left for us once we become resistant to docetaxel (DOC) plus prednisone, which is the last FDA approved, standard of care treatment available for advanced hormone refractory prostate cancer? There has been some studies that indicate after a “vacation period” similar to what many of us do with a first line hormone blockade, [...]